Loading…
BH3-only proteins Mcl-1 and Bim as well as endonuclease G are targeted in spongistatin 1–induced apoptosis in breast cancer cells
Spongistatin 1, a marine experimental substance with chemotherapeutic potential, induces apoptosis and inhibits clonogenic survival of MCF-7 cells. Regarding the apoptotic signaling pathways of spongistatin 1, we present two major facts. Firstly, spongistatin 1–induced cell death, mainly caspase-ind...
Saved in:
Published in: | Molecular cancer therapeutics 2009-10, Vol.8 (10), p.2914-2925 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Spongistatin 1, a marine experimental substance with chemotherapeutic potential, induces apoptosis and inhibits clonogenic
survival of MCF-7 cells. Regarding the apoptotic signaling pathways of spongistatin 1, we present two major facts. Firstly,
spongistatin 1–induced cell death, mainly caspase-independent, involves the proapoptotic proteins apoptosis-inducing factor
and endonuclease G. Both proteins translocate from mitochondria to the nucleus and contribute to spongistatin 1–mediated apoptosis
as shown via gene silencing. Secondly, spongistatin 1 acts as a tubulin depolymerizing agent and is able to free the proapoptotic
Bcl-2 family member Bim from its sequestration both by the microtubular complex and by the antiapoptotic protein Mcl-1. Silencing
of Bim by small interfering RNA leads to a diminished translocation of apoptosis-inducing factor and endonuclease G to the
nucleus and subsequently reduces apoptosis rate. Thus, we identified Bim as an important factor upstream of mitochondria executing
a central role in the caspase-independent apoptotic signaling pathway induced by spongistatin 1. Taken together, spongistatin
1 is both a valuable tool for the characterization of apoptotic pathways and a promising experimental anticancer drug. [Mol
Cancer Ther 2009;8(10):2914–25] |
---|---|
ISSN: | 1535-7163 1538-8514 |
DOI: | 10.1158/1535-7163.MCT-08-1179 |